Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Recursion Pharmaceuticals Inc.
Headquarters: Salt Lake City, UT, United States of America
Website: https://www.recursion.com/
Year Founded: 2013
Status: Public
Industry Sector: HealthTechnology
CEO: Chistopher C. Gibson, MD, PhD
Number Of Employees: N/A
Enterprise Value: $1,364,737,307
PE Ratio: -2.39
Exchange/Ticker 1: NASDAQ:RXRX
Exchange/Ticker 2: N/A
Latest Market Cap: $1,595,904,256
BioCentury | Mar 19, 2025
Management Tracks
CFO Brian Stephenson exits Bridgebio
Plus: CEO Edward Kayne steps down at Stoke, and updates from Collegium, Pyxis, Recursion and Tonix
BioCentury | Mar 14, 2025
Management Tracks
Rui Santos Ivo elected as new chair at EMA
Plus: Jane Chung named CEO of Sutro after strategic review, and Richard Law becomes CBO at Haya
BioCentury | Feb 20, 2025
Finance
Bambusa’s $90M series A; Recursion-backed accelerator’s ‘pre-seed’ fund: Venture Report
Plus fundings around the globe for Eg 427, Atrandi and Reverb
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
BioCentury | Jan 22, 2025
Management Tracks
Fabrice Chouraqui to become CEO of Pharming
Plus: Woodcock, Kim join Friends of Cancer Research’s board and updates from Recursion, Medtronic and more
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 7, 2025
Management Tracks
John Finn named CSO of Basecamp
Plus: Iambic hires Michael Secora and updates from Septerna, Beigene, Perspective, Halia and more
BioCentury | Oct 11, 2024
Product Development
Discovery through perturbation: taking causality into your own hands
A company’s experimental setup and scale shape the type of AI it uses and questions it can ask
BioCentury | Oct 7, 2024
Discovery & Translation
Causal biology in the age of big data
Where do you start? Patient data might sound more obvious, but human cell-based models have advantages
Items per page:
1 - 10 of 66